Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1927 1
1930 1
1938 1
1939 1
1941 2
1943 1
1945 5
1946 19
1947 32
1948 33
1949 48
1950 42
1951 51
1952 46
1953 53
1954 45
1955 56
1956 63
1957 60
1958 74
1959 69
1960 75
1961 78
1962 72
1963 76
1964 118
1965 112
1966 103
1967 148
1968 188
1969 206
1970 267
1971 316
1972 336
1973 346
1974 335
1975 313
1976 414
1977 371
1978 355
1979 379
1980 441
1981 435
1982 466
1983 530
1984 511
1985 550
1986 538
1987 516
1988 541
1989 564
1990 512
1991 554
1992 580
1993 532
1994 597
1995 658
1996 660
1997 683
1998 800
1999 793
2000 848
2001 964
2002 1005
2003 1143
2004 1209
2005 1314
2006 1385
2007 1599
2008 1615
2009 1848
2010 2009
2011 2126
2012 2214
2013 2455
2014 2536
2015 2539
2016 2720
2017 2726
2018 2733
2019 2979
2020 3398
2021 3647
2022 3444
2023 3482
2024 1011

Text availability

Article attribute

Article type

Publication date

Search Results

64,018 results

Results by year

Filters applied: . Clear all
Page 1
Morphology of inflammatory bowel diseases (IBD).
Fabián O, Kamaradová K. Fabián O, et al. Cesk Patol. 2022 Spring;58(1):27-37. Cesk Patol. 2022. PMID: 35387455 Review. English.
Inflammatory bowel diseases (IBD) represent a group of chronic systemic inflammatory conditions with predilection to gastrointestinal tract and include Crohns disease and ulcerative colitis. If the IBD cannot be further specified, a term unclassified IBD is used. Histopath …
Inflammatory bowel diseases (IBD) represent a group of chronic systemic inflammatory conditions with predilection to gastrointestinal tract …
Blockade of IL-23: What is in the Pipeline?
Parigi TL, Iacucci M, Ghosh S. Parigi TL, et al. J Crohns Colitis. 2022 May 11;16(Supplement_2):ii64-ii72. doi: 10.1093/ecco-jcc/jjab185. J Crohns Colitis. 2022. PMID: 35553666 Free PMC article. Review.
Interleukin 23 [IL-23] plays a key role in the pathogenesis of both Crohn's disease [CD] and ulcerative colitis [UC], promoting a Th17 cell-related immune response. ...
Interleukin 23 [IL-23] plays a key role in the pathogenesis of both Crohn's disease [CD] and ulcerative colitis [UC], promotin …
Crohn Disease: Epidemiology, Diagnosis, and Management.
Feuerstein JD, Cheifetz AS. Feuerstein JD, et al. Mayo Clin Proc. 2017 Jul;92(7):1088-1103. doi: 10.1016/j.mayocp.2017.04.010. Epub 2017 Jun 7. Mayo Clin Proc. 2017. PMID: 28601423 Review.
Crohn disease is a chronic idiopathic inflammatory bowel disease condition characterized by skip lesions and transmural inflammation that can affect the entire gastrointestinal tract from the mouth to the anus. For this review article, we performed a review of articles in
Crohn disease is a chronic idiopathic inflammatory bowel disease condition characterized by skip lesions and transmural inflammation
Efficacy of JAK inhibitors in Crohn's Disease.
Rogler G. Rogler G. J Crohns Colitis. 2020 Aug 1;14(Supplement_2):S746-S754. doi: 10.1093/ecco-jcc/jjz186. J Crohns Colitis. 2020. PMID: 31781755 Free PMC article. Review.
Inhibition of Janus kinases [JAKs] in Crohn's disease [CD] patients has shown conflicting results in clinical trials. ...
Inhibition of Janus kinases [JAKs] in Crohn's disease [CD] patients has shown conflicting results in clinical trials. ...
Surgical treatment of Crohns disease in children in the era of biological treatment.
Dotlačil V, Škába R, Rousková B, Poš L, Kučerová B, Coufal Š, Lerchová T, Rygl M. Dotlačil V, et al. Rozhl Chir. 2022 Winter;101(2):56-60. doi: 10.33699/PIS.2022.101.2.56-60. Rozhl Chir. 2022. PMID: 35240841 Review. English.
INTRODUCTION: The incidence of Crohns disease in the paediatric population has been increasing and requires surgical treatment in addition to conservative therapy. ...CONCLUSION: According to current knowledge, no association was found between biological treatment in the p …
INTRODUCTION: The incidence of Crohns disease in the paediatric population has been increasing and requires surgical treatment in add …
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management.
Gomollón F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay JO, Peyrin-Biroulet L, Cullen GJ, Daperno M, Kucharzik T, Rieder F, Almer S, Armuzzi A, Harbord M, Langhorst J, Sans M, Chowers Y, Fiorino G, Juillerat P, Mantzaris GJ, Rizzello F, Vavricka S, Gionchetti P; ECCO. Gomollón F, et al. J Crohns Colitis. 2017 Jan;11(1):3-25. doi: 10.1093/ecco-jcc/jjw168. Epub 2016 Sep 22. J Crohns Colitis. 2017. PMID: 27660341 Free article.
This paper is the first in a series of two publications relating to the European Crohn's and Colitis Organisation [ECCO] evidence-based consensus on the diagnosis and management of Crohn's disease and concerns the methodology of the consensus process, …
This paper is the first in a series of two publications relating to the European Crohn's and Colitis Organisation [ECCO] evide …
Prioritization in inflammatory bowel disease therapy.
Herrlinger KR, Stange EF. Herrlinger KR, et al. Expert Rev Gastroenterol Hepatol. 2023 Jul-Dec;17(8):753-767. doi: 10.1080/17474124.2023.2240699. Epub 2023 Jul 26. Expert Rev Gastroenterol Hepatol. 2023. PMID: 37480322 Review.
This review provides an aid to pending therapy decisions. AREAS COVERED: In this review, we analyze the evidence for Crohn's disease as well as ulcerative colitis in order to optimize and 'personalize' the choice of therapy, especially in difficult cases. The releva …
This review provides an aid to pending therapy decisions. AREAS COVERED: In this review, we analyze the evidence for Crohn's d …
Ustekinumab in Crohn's Disease: New Data for Positioning in Treatment Algorithm.
D'Amico F, Peyrin-Biroulet L, Danese S. D'Amico F, et al. J Crohns Colitis. 2022 May 11;16(Supplement_2):ii30-ii41. doi: 10.1093/ecco-jcc/jjac011. J Crohns Colitis. 2022. PMID: 35553665 Free PMC article. Review.
The treatment of patients with moderate to severe Crohn's disease [CD] is still challenging. Therapeutic options include steroids, immunosuppressants, anti-TNFalpha agents, vedolizumab, and ustekinumab. ...
The treatment of patients with moderate to severe Crohn's disease [CD] is still challenging. Therapeutic options include stero …
64,018 results
You have reached the last available page of results. Please see the User Guide for more information.